Rich Pharmaceuticals (RCHA) 10-K 5 Sep 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2017	Jul. 10, 2017	Sep. 30, 2016
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	1,504,389
Document Type	10-K
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 527,878
Entity Common Stock, Shares Outstanding		350,136,570
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Current Assets
Cash and equivalents	$ 40,903
Prepaid expenses		2,800
Notes receivable	10,000
Total Current Assets	50,903	2,800
Property and equipment, net	2,125	3,731
TOTAL ASSETS	53,028	6,531
Current Liabilities
Bank overdraft		2,948
Accounts payable	349,635	1,139,431
Accrued expenses	937,783	530,150
Due to related parties	49,395	76,913
Note payable	920,000
Convertible notes payable, net of debt discount $356,819 and $88,366 for March 31, 2017 and 2016	514,075	201,879
Derivative liabilities	2,607,959	446,912
Total Current Liabilities	5,378,847	2,398,233
Long-term Liabilities
Convertible notes payable, net of debt discount
Derivative liabilities
Total Long-term Liabilities
Total Liabilities	5,378,847	2,398,233
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000
Common stock, $0.001 par value, 2,000,000,000 shares authorized, 101,446,215 and 10,818,213 shares issued and outstanding,	101,446	10,818
Additional paid-in capital	7,011,504	6,794,920
Accumulated deficit	(12,444,769)	(9,203,440)
Total Stockholders Deficit	(5,325,819)	(2,391,702)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 53,028	$ 6,531

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ .001	$ .001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Issued	101,446,215	10,818,213
Preferred Stock, Par Value	$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Issued	6,000,000	6,000,000
Convertible notes payable, debt discount	$ 356,819	$ 88,366

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses	45,554	16,000
Office expenses	123,619	110,600
Depreciation expense	1,606	799
Wages and taxes	362,626	383,937
Professional fees	220,411	267,778
Regulatory fees	19,018	29,356
Research and development	71,930	16,823
Stock-based compensation	48,016	240,999
Travel, meals and entertainment	59,037	51,313
TOTAL OPERATING EXPENSES	951,817	1,117,605
LOSS FROM OPERATIONS	(951,817)	(1,118)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(272,184)	(531,638)
Change in value of derivative liability	(1,112,538)	563,432
Derivative expense	(608,949)	(497,213)
Interest expense	(224,828)	(185,136)
Interest expense related party	(536)	(300)
Loss on extinguishment of debt	(70,477)
Other Income Total	(2,289,512)	(650,855)
LOSS BEFORE PROVISION FOR INCOME TAXES	(3,241,329)	(1,768,460)
PROVISION FOR INCOME TAXES
NET LOSS	$ (3,241,329)	$ (1,768,460)
NET LOSS PER SHARE: BASIC AND DILUTED	$ (0.08)	$ (0.47)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	41,403,529	3,801,064

Statement of Stockholders Equit

Statement of Stockholders Equity (Deficit) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Deficit Accumulated	Total
Beginning balance, shares at Mar. 31, 2015	6,000,000	10,818,213
Beginning balance, amount at Mar. 31, 2015	$ 6,000	$ 10,818	$ 6,794,920	$ (9,203,440)	$ (2,391,702)
Stock issued for services, amount			48,016		48,016
Issuance of common stock for cash, shares		317,519
Issuance of common stock for cash, amount		$ 317	48,838		49,155
Warrants issued for services, amount			45,466		45,466
Stock issued for debt conversion, shares		90,628,002
Stock issued for debt conversion, amount		$ 90,628	60,314		150,942
Derivative liability closed to APIC			62,788		62,788
Stock option modification			56,779		56,779
Net loss				(3,274,663)	(1,768,460)
Ending balance, shares at Mar. 31, 2016	6,000,000	10,818,213
Ending balance, amount at Mar. 31, 2016	$ 6,000	$ 10,818	6,794,920	(9,203,440)	(2,391,702)
Stock issued for services, amount			48,016		48,016
Warrants issued for services, amount			45,466		45,466
Stock issued for debt conversion, shares		90,628,002
Stock issued for debt conversion, amount		$ 90,628	60,314		150,942
Derivative liability closed to APIC			62,788		62,788
Net loss				(3,241,329)	(3,241,329)
Ending balance, shares at Mar. 31, 2017	6,000,000	101,446,215
Ending balance, amount at Mar. 31, 2017	$ 6,000	$ 101,446	$ 7,011,504	$ (12,444,769)	$ (5,325,819)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (3,241,329)	$ (1,768,460)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	1,606	799
Amortization of debt discount	272,184	531,638
Change in value of derivative liability	1,112,538	(563,432)
Derivative expense	608,949	497,213
Loss on extinguishment of debt	70,477
Interest converted into stock	11,010
Warrants issued for services	45,466
Stock-based compensation	48,016	240,999
Changes in operating assets and liabilities:
Decrease in prepaid expenses	2,800	4,778
Increase (decrease) in bank overdraft	(2,948)	2,948
Increase in accounts payable	110,204	229,159
Increase in accrued expenses	407,633	329,259
Net Cash Used by Operating Activities	(553,394)	(495,099)
CASH FLOWS FROM INVESTING ACTIVITY:
Increase in notes receivable	(10,000)
Acquisition of assets		(3,741)
Net Cash Used by Investing Activities	(10,000)	(3,741)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties	(27,518)	70,846
Proceeds from sale of common stock and warrants		49,155
Proceeds from issuance of note payable	20,000
Proceeds from issuance of convertible notes payable	611,815	362,947
Net Cash Provided by Financing Activities	604,297	482,948
Net Increase (Decrease) in Cash and Cash Equivalents	40,903	(15,892)
Cash and cash equivalents, beginning of period		15,892
Cash and cash equivalents, end of period	40,903
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Accounts payable converted into note payable	900,000
Warrants issued for accrued expenses	36,000
Original issue discounts recorded on notes payable	30,000	12,900
Debt discounts recorded on convertible notes payable	543,858	498,544
Debt/interest converted into common stock and contributed capital	$ 389,100	$ 602,374

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2017 and 2016 the Company had $40,903 and $-, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2017 or March 31, 2016. As of March 31, 2017, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment

Property and equipment	12 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment, recorded at cost, consisted of the following as of March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,035 ) (1,429 ) Property and equipment, net $ 2,125 $ 3,731 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $1,606 and $799 for the periods ended March 31, 2017 and 2016, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Mar. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Wages and taxes $ 829,231 $ 514,713 Accrued interest 108,552 15,437 Total accrued expenses $ 937,783 $ 530,150

Related Party Debt and Transact

Related Party Debt and Transactions	12 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Debt and Transactions	During the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended March 31, 2017 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest. There is a total due of $12,280 as of March 31, 2017. Interest accrued on the note as of March 31, 2017 and 2016 was $903 and $267, respectively. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending March 31, 2017 received an additional $14,450, and has repaid $36,300 of these loans leaving a total due of $350 as of March 31, 2017. These loans are deemed to be short-term and are payable at the discretion of the Company. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years, and has been extended for an additional two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 1,500 shares of common stock at an exercise price of $40.00 per share. The CEO earned $275,000 and $275,000 for the periods ended March 31, 2017 and 2016 (respectively) as a result of this agreement, these amounts contribute to the $645,945 and $395,630 of officer compensation which is included in accrued expenses, as of March 31, 2017 and 2016.

Note Payable

Note Payable	12 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Note Payable	On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $74,959 as of March 31, 2017. On February 21, 2017, the Company issued a non-secured promissory note in the amount of $20,000. The note is due on August 21, 2017 and bears interest at 8% per annum. The loan was in payment for professional fees related to an equity financing agreement dated February 21, 2017, thus no cash was received by the Company. Accrued interest was $167 as of March 31, 2017.

Convertible Note Payable

Convertible Note Payable	12 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Convertible Note Payable	On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 70,185 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 8,892 shares of common stock leaving a remaining balance of accrued interest of $0 as of March 31, 2016. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 9,091 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 93,980 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 35,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 43,234 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 39,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $55,000 in principal and $3,553 in accrued interest into 140,682 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 264,514 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 252,358 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 423,500 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 619,652 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. On February 22, 2017, this note was purchased for a renegotiated face value of $59,799, including accrued interest of $6,416 and incurring a loss on extinguisment of debt of $5,403. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 442,702 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 259,261 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 2,886,693 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 2,324,229 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 796,236 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 60,778 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 2,650 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 906,763 shares of common stock. During the period ending March 31, 2017 the note holder converted $60,439 in principal and $6,839 in accrued interest into 44,551,004 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of . On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 129,566 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending the note holder converted $15,000 in principal and $939 in accrued interest into 4,351,619 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2017. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016, with a revised due date of June 23, 2017. The loan becomes convertible on , 2015, the issue date of the note. The loan can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 1,796,394 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period prior to the conversion date. Interest accrued as of is $7,194. The Company is in default on the balance of this note. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. During the period ending the note holder converted $16,745 in principal and $1,380 in interest into 3,325,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or before June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $134,214, including accrued interest of $5,226 and incurring a loss on extinguishment of debt of $44,738. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of March 31, 2017 the accrued interest balance is $3,449. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or before July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On January 5, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $285,000. The note bears interest at the rate of 10%, contains a $30,000 OID, and must be repaid by October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or January 5, 2017, On February 20, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $243,313, which consolidated unpaid convertible notes dated March 9, 2015; September 4, 2015; December 29, 2015; February 25, 2016; March 24, 2016; May 25, 2016; June 8, 2016. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 20, 2017, leaving a remaining balance of $208,943 On February 21, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $15,000. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 21, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $59,799, which refinances an unpaid convertible note dated February 5, 2015. The note bears interest at the rate of 10%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On February 22, 2017, the Company issued a 10% Convertibe Redeemable Promissory Note in the principal amount of $20,900, which refinances an unpaid convertible note dated May 6, 2015. The note bears interest at the rate of 10%, and must be repaid by October 22, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017,

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Derivative Liabilities	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending March 31, 2017 and March 31, 2016: $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $33,000 note dated January 9, 2015; $54,000 note dated February 5, 2015; $66,780 note dated February 17, 2015;$58,300 note dated March 2, 2015; $55,000 note dated March 9, 2015; $29,680 note dated March 26, 2015; $68,900 note dated May 5, 2015; $10,500 note dated May 6, 2015; $16,500 note dated May 27, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; $7,500 note dated March 24, 2016; $30,000 note dated May 25, 2016; $84,250 note dated June 8, 2016; $56,000 note dated June 23, 2016; $58,000 note dated July 7, 2016; $285,000 note dated January 5, 2017; $243,313 note dated February 20, 2017; $15,000 note dated February 21, 2017; $59,799 note dated February 22, 2017; $20,900 note dated February 22, 2017. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended March 31, 2017, the Company recorded a total change in the fair market value of the derivative liabilities of $1,112,538. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0001-$0.0002, exercise price of $0.00005 - $0.0006, dividend yield of zero, years to maturity of 0.060270 – .64660, a risk free rate of 0.53% - 0.91%, and annualized volatility of 0% - 841%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates for the period ending March 31, 2017, the Company recognized debt discounts related to the conversion features totaling $563,858 and a derivative expense of $852,262 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of March 31, 2017, unamortized debt discount, including original issue discounts totaled $356,819. The derivative liabilities totaled $2,607,959 as of March 31, 2017, of which $- related to long-term debt.

Equity Transactions

Equity Transactions	12 Months Ended
	Mar. 31, 2017
Equity Transactions
Equity Transactions	The Company has 2,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 41,384 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 250,128 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 131,261 common shares. On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 125 units at $600.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $1,000.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 125 units at $600.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $1,000.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2015, the Company issued 45,000 units at $0.40 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.40 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 15, 2015, the Company issued 200,000 units at $0.20 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.20 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date June 9, 2015 Dec 15,2015 March 30, 2017 Warrants 45,000 200,000 9,200,000 Stock price on grant date $0.40 $0.20 $0.002 Exercise price $0.40 $0.20 $0.002 Expected life 5 year 5 year 5 year Volatility 98% 98% 120% Risk-free rate 1.74% 1.71% 1.96% Calculated value $13,259 $29,612 $15,278 Fair value allocation of proceeds $13,259 $29,612 $45,466 The following is a summary of the warrant activity for the period March 31, 2016 to March 31, 2017: Number of warrants Weighted average exercise price Outstanding, March 31, 2016 246,533 $3.84 Granted 9,200,000 $0.002 Exercised - - Outstanding, March 31, 2017 9,446,556 $0.102 On April 22, 2015, the Company sold 5,019 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 77,123 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. On July 7, 2015, the Company sold 80,971 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services. On July 15, 2015, the Company sold 71,964 shares of common stock for $10,075 in cash. On October 27, 2015, the Company sold 82,442 shares of common stock for $11,542 in cash. On February 8, 2016, the Company approved a change in the authorized shares of common stock to 4,000,000,000 shares. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. On May 9, 2017, the Company approved the reduction of the number of authorized $0.001 par value common stock from 40,000,000,000 common shares to 2,000,000,000 common shares. These financial statements reflect the change in authorized stock. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. During the year ended March 31, 2014, the Company granted 23,752 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 33,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $38.40 per share and $600.00 per share, to $3.40 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. During the periods ended March 31, 2017 and March 31, 2016, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 20,556 $0.81000 April 6, 2015 $10,000 10,482 $0.95400 April 8, 2015 $15,309 22,678 $0.67500 April 8, 2015 $20,001 22,727 $0.88000 April 9, 2015 $14,320 16,273 $0.88000 April 14, 2015 $10,000 11,848 $0.84400 April 16, 2015 $1,918 2,650 $0.72380 April 21, 2015 $10,000 12,987 $0.77000 April 29, 2015 $15,000 19,481 $0.77000 May 4, 2015 $5,083 6,573 $0.77320 May 12, 2015 $28,456 45,169 $0.63000 May 20, 2015 $20,199 47,382 $0.42620 May 20, 015 $17,240 39,182 $0.44000 May 27, 2015 $13,568 35,090 $0.38660 May 29, 2015 $15,000 44,118 $0.34000 June 11, 2015 $9,897 47,130 $0.21000 June 16, 2015 $14,100 58,750 $0.24000 June 16, 2015 $13,565 56,521 $0.24000 June 22, 2015 $7,415 61,792 $0.12000 June 22, 2015 $14,384 123,996 $0.11600 June 23, 2015 $7,752 64,600 $0.12000 September 16, 2015 $7,974 88,602 $0.09000 September 28, 2015 $10,000 83,333 $0.12000 September 29, 2015 $10,620 88,500 $0.12000 October 7, 2015 $2,250 18,750 $0.12000 October 7, 2015 $8,400 70,000 $0.12000 October 19, 2015 $9,720 81,000 $0.12000 November 2, 2015 $4,424 98,306 $0.04500 November 23, 2015 $10,000 83,333 $0.12000 November 30, 2015 $16,844 129,566 $0.13000 December 9, 2015 $1,746 38,800 $0.04500 December 17, 2015 $5,332 45,966 $0.11600 December 28, 2015 $1,341 29,810 $0.04500 December 28, 2015 $17,700 147,500 $0.12000 December 28, 2015 $14,305 119,208 $0.12000 December 28, 2015 $14,963 128,996 $0.11600 December 29, 2015 $8,395 69,958 $0.12000 December 29, 2015 $7,670 63,917 $0.12000 December 30, 2015 $6,651 147,812 $0.04500 January 1, 2016 $28,500 219,231 $0.13000 January 4, 2016 $19,339 161,161 $0.12000 January 5, 2016 $8,107 180,161 $0.04500 January 6, 2016 $16,070 133,917 $0.12000 January 6, 2016 $16,597 143,080 $0.11600 February 16 ,2016 $1,424 211,020 $0.00680 February 17, 2016 $12,800 422,164 $0.03040 February 23, 2016 $4,640 210,909 $0.02200 February 23, 2016 $3,086 210,044 $0.01460 February 24, 2016 $1,492 220,999 $0.00680 February 25, 2016 $3,000 131,949 $0.02280 February 25, 2016 $4,640 210,909 $0.02200 March 1, 2016 $1,313 291,723 $0.00440 March 2, 2016 $4,600 291,582 $0.01580 March 2, 2016 $1,650 129,321 $0.01280 March 2, 2016 $9,332 582,500 $0.01600 March 7, 2016 $2,799 327,315 $0.00860 March 11, 2016 $1,924 207,375 $0.00920 March 14, 2016 $2,245 356,289 $0.00640 March 15, 2016 $3,329 372,705 $0.00900 March 15, 2016 $5,210 572,500 $0.00920 March 22, 2016 $2,419 447,894 $0.00540 March 22, 2016 $2,367 360,023 $0.00660 March 22, 2016 $5,315 584,100 $0.00920 March 28, 2016 $1,986 447,939 $0.00440 March 31, 2016 Total $602,376 9,730,152 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002 (2) Effective April 6, 2015, the Company approved the re-pricing of all 135,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $3.40 per share, to $1.60 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 185.627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $0.40 per share, to $0.40 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017 The following is a summary of the option activity for the period March 31, 2016 through March 31, 2017: Number of options Weighted average exercise price Outstanding, March 31, 2016 228,627 $0.20 Granted 29,000,000 $0.002 Exercised - - Expired - - Outstanding, March 31, 2017 29,228,627 $0.004 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined.

Commitments and Contigencies

Commitments and Contigencies	12 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Commitments and Contingencies	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800. On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	As of March 31, 2017, the Company had net operating loss carry forwards of approximately $12,444,769 that may be available to reduce future years’ taxable income in varying amounts through 2034. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following for the years ended March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Federal income tax benefit attributable to: Current operations $ 1,102,052 $ 601,276 Less: valuation allowance (1,102,052 ) (601,276 ) Net provision for Federal income taxes $ — $ — The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of March 31, 2017 and 2016: March 31, 2017 March 31, 2016 Deferred tax asset attributable to: Net operating loss carryover $ 4,231,221 $ 3,129,170 Less: valuation allowance (4,231,221 ) (3,129,170 ) Net deferred tax asset $ — $ — Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $12,444,769 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Subsequent Events	On April 4, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $71,457, which refinances an unpaid convertible note dated January 22, 2016. The note bears interest at the rate of 8%, and must be repaid by January 4, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On April 5, 2017, the Company converted $6,004 in principle and $229 in interest on a convertible note payable into 5,300,000 shares of common stock. On April 10, 2017, the Company converted $6,363 in principle and $222 in interest on a convertible note payable into 5,600,000 shares of common stock. On April 11, 2017, the Company converted $6,004 in principle and $43 in interest on a convertible note payable into 5,850,000 shares of common stock. On April 18, 2017, the Company converted $7,000 in principle and $291 in interest on a convertible note payable into 6,200,000 shares of common stock. On April 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $115,000. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $5000 to cover transaction costs, the note must be repaid by January 30, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On April 20, 2017, the Company converted $7,564 in principle and $80 in interest on a convertible note payable into 6,500,000 shares of common stock. On April 21, 2017, the Company converted $16,426 in principle and $38 in interest on a convertible note payable into 14,000,000 shares of common stock. On April 25, 2017, the Company converted $17,148 in principle and $139 in interest on a convertible note payable into 14,700,000 shares of common stock. On April 26, 2017, the Company converted $25,000 in principle and $1,600 in interest on a convertible note payable into 26,600,000 shares of common stock. On May 1, 2017, the Company converted $8,514 in principle and $186 in interest on a convertible note payable into 14,500,000 shares of common stock. On May 9, 2017, the Company approved the reduction of the number of authorized $0.001 par value common stock from 40,000,000,000 common shares to 2,000,000,000 common shares. On May 15, 2017 the Company loaned $5,300 to a related party with a promissory note due in 1 year and stipulating a 0% interest rate. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. On June 13, 2017, the Company converted $0 in principle and $1,200 in interest on a convertible note payable into 10,000,000 shares of common stock. On June 16, 2017, the Company converted $1,158 in principle and $142 in interest on a convertible note payable into 11,000,000 shares of common stock. On June 16, 2017, the Company converted $1,795 in principle and $135 in interest on a convertible note payable into 19,299,400 shares of common stock. On June 20, 2017, the Company converted $1,276 in principle and $116 in interest on a convertible note payable into 11,600,000 shares of common stock. On June 21, 2017, the Company converted $2,150 in principle and $164 in interest on a convertible note payable into 23,139,900 shares of common stock. On June 22, 2017, the Company converted $1,413 in principle and $57 in interest on a convertible note payable into 12,250,000 shares of common stock. On June 22, 2017, the Company converted $1,590 in principle and $0 in interest on a convertible note payable into 13,250,000 shares of common stock. On June 26, 2017, the Company converted $1,688 in principle and $112 in interest on a convertible note payable into 15,000,000 shares of common stock. On June 29, 2017, the Company converted $1,897 in principle and $83 in interest on a convertible note payable into 16,500,000 shares of common stock. On July 3, 2017, the Company converted $1,979 in principle and $109 in interest on a convertible note payable into 17,400,000 shares of common stock. On July 7, 2017, the Company entered into a two year consulting agreement with a related party. The agreement stipulates payment for scientific, clinical and regulatory services to the related party of $180,000 per year ($15,000 per month) with the option of common stock payment in lieu of cash. On July 11, 2017, Rich Pharmaceuticals, Inc. (the “Company”) entered into a Support and Collaboration Agreement (the “Collaboration Agreement”) with Mega Bridge, Inc., a Nevada corporation to be renamed “Hypgen”) (“Hypgen”), to support Hypgen’s development of treatments for Parkinson’s Disease. Under the terms of the agreement, the Company will provide data, raw materials and advisory support to Hypgen to assist Hypgen with their development of treatments for Parkinson’s Disease and the associated regulatory approval process. In exchange, Hypgen will pay the Company $100,000 and issue the Company 15,000,000 shares of Hypgen common stock. The Company plans to dividend five million of these shares to its shareholders at such time as the Company completes the necessary corporate and regulatory requirements regarding payment of a dividend. On July 12, 2017, the Company converted $0 in principle and $2,088 in interest on a convertible note payable into 17,400,000 shares of common stock. On July 13, 2017, the Company converted $1,344 in principle and $1,140 in interest on a convertible note payable into 13,800,000 shares of common stock. On July 14, 2017, the Company converted $3,358 in principle and $16 in interest on a convertible note payable into 19,000,000 shares of common stock. On July 3, 2017, the Company converted $3,314 in principle and $60 in interest on a convertible note payable into 19,000,000 shares of common stock. On July 20, 2017, the Company converted $3,554 in principle and $28 in interest on a convertible note payable into 19,900,000 shares of common stock. On July 24, 2017, the Company converted $6,217 in principle and $53 in interest on a convertible note payable into 20,900,000 shares of common stock. On July 25, 2017, the Company converted $6,022 in principle and $848 in interest on a convertible note payable into 22,900,000 shares of common stock. On July 28, 2017, the Company converted $7,089 in principle and $111 in interest on a convertible note payable into 24,000,000 shares of common stock. On August 2, 2017, the Company converted $7,035 in principle and $165 in interest on a convertible note payable into 24,000,000 shares of common stock. On August 4, 2017, the Company converted $8,942 in principle and $58 in interest on a convertible note payable into 25,000,000 shares of common stock. On August 8, 2017, the Company converted $11,022 in principle and $97 in interest on a convertible note payable into 26,475,000 shares of common stock. On August 11, 2017, the Company converted $13,920 of a convertible note payable into 29,000,000 shares of common stock. On August 16, 2017, the Company converted $12,810 of a convertible note payable into 30,500,000 shares of common stock. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2017 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Nature of Business	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2017 and 2016 the Company had $40,903 and $-, respectively, of unrestricted cash.
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end.
Property and Equipment	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.
Long-Lived and Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2017 or March 31, 2016. As of March 31, 2017, the derivative liabilities were considered a level 2 item; see Note 8.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Research and Development	The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share.
Basic loss per share	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.
Recent Accounting Pronouncements	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	March 31, 2017 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,035 ) (1,429 ) Property and equipment, net $ 2,125 $ 3,731

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Mar. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	March 31, 2017 March 31, 2016 Wages and taxes $ 829,231 $ 514,713 Accrued interest 108,552 15,437 Total accrued expenses $ 937,783 $ 530,150

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Schedule of Value of Warrants	Date June 9, 2015 Dec 15,2015 March 30, 2017 Warrants 45,000 200,000 9,200,000 Stock price on grant date $0.40 $0.20 $0.002 Exercise price $0.40 $0.20 $0.002 Expected life 5 year 5 year 5 year Volatility 98% 98% 120% Risk-free rate 1.74% 1.71% 1.96% Calculated value $13,259 $29,612 $15,278 Fair value allocation of proceeds $13,259 $29,612 $45,466
Schedule of Warrant Activity	Number of warrants Weighted average exercise price Outstanding, March 31, 2016 246,533 $3.84 Granted 9,200,000 $0.002 Exercised - - Outstanding, March 31, 2017 9,446,556 $0.102
Schedule of Conversions of Common Stock	Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 20,556 $0.81000 April 6, 2015 $10,000 10,482 $0.95400 April 8, 2015 $15,309 22,678 $0.67500 April 8, 2015 $20,001 22,727 $0.88000 April 9, 2015 $14,320 16,273 $0.88000 April 14, 2015 $10,000 11,848 $0.84400 April 16, 2015 $1,918 2,650 $0.72380 April 21, 2015 $10,000 12,987 $0.77000 April 29, 2015 $15,000 19,481 $0.77000 May 4, 2015 $5,083 6,573 $0.77320 May 12, 2015 $28,456 45,169 $0.63000 May 20, 2015 $20,199 47,382 $0.42620 May 20, 015 $17,240 39,182 $0.44000 May 27, 2015 $13,568 35,090 $0.38660 May 29, 2015 $15,000 44,118 $0.34000 June 11, 2015 $9,897 47,130 $0.21000 June 16, 2015 $14,100 58,750 $0.24000 June 16, 2015 $13,565 56,521 $0.24000 June 22, 2015 $7,415 61,792 $0.12000 June 22, 2015 $14,384 123,996 $0.11600 June 23, 2015 $7,752 64,600 $0.12000 September 16, 2015 $7,974 88,602 $0.09000 September 28, 2015 $10,000 83,333 $0.12000 September 29, 2015 $10,620 88,500 $0.12000 October 7, 2015 $2,250 18,750 $0.12000 October 7, 2015 $8,400 70,000 $0.12000 October 19, 2015 $9,720 81,000 $0.12000 November 2, 2015 $4,424 98,306 $0.04500 November 23, 2015 $10,000 83,333 $0.12000 November 30, 2015 $16,844 129,566 $0.13000 December 9, 2015 $1,746 38,800 $0.04500 December 17, 2015 $5,332 45,966 $0.11600 December 28, 2015 $1,341 29,810 $0.04500 December 28, 2015 $17,700 147,500 $0.12000 December 28, 2015 $14,305 119,208 $0.12000 December 28, 2015 $14,963 128,996 $0.11600 December 29, 2015 $8,395 69,958 $0.12000 December 29, 2015 $7,670 63,917 $0.12000 December 30, 2015 $6,651 147,812 $0.04500 January 1, 2016 $28,500 219,231 $0.13000 January 4, 2016 $19,339 161,161 $0.12000 January 5, 2016 $8,107 180,161 $0.04500 January 6, 2016 $16,070 133,917 $0.12000 January 6, 2016 $16,597 143,080 $0.11600 February 16 ,2016 $1,424 211,020 $0.00680 February 17, 2016 $12,800 422,164 $0.03040 February 23, 2016 $4,640 210,909 $0.02200 February 23, 2016 $3,086 210,044 $0.01460 February 24, 2016 $1,492 220,999 $0.00680 February 25, 2016 $3,000 131,949 $0.02280 February 25, 2016 $4,640 210,909 $0.02200 March 1, 2016 $1,313 291,723 $0.00440 March 2, 2016 $4,600 291,582 $0.01580 March 2, 2016 $1,650 129,321 $0.01280 March 2, 2016 $9,332 582,500 $0.01600 March 7, 2016 $2,799 327,315 $0.00860 March 11, 2016 $1,924 207,375 $0.00920 March 14, 2016 $2,245 356,289 $0.00640 March 15, 2016 $3,329 372,705 $0.00900 March 15, 2016 $5,210 572,500 $0.00920 March 22, 2016 $2,419 447,894 $0.00540 March 22, 2016 $2,367 360,023 $0.00660 March 22, 2016 $5,315 584,100 $0.00920 March 28, 2016 $1,986 447,939 $0.00440 March 31, 2016 Total $602,376 9,730,152 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002
Schedule of Value of Options	Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017
Schedule of Option Activity	Number of options Weighted average exercise price Outstanding, March 31, 2016 228,627 $0.20 Granted 29,000,000 $0.002 Exercised - - Expired - - Outstanding, March 31, 2017 29,228,627 $0.004

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Federal Income Tax	March 31, 2017 March 31, 2016 Federal income tax benefit attributable to: Current operations $ 1,102,052 $ 601,276 Less: valuation allowance (1,102,052 ) (601,276 ) Net provision for Federal income taxes $ — $ —
Schedule of Deferred Tax Asset	March 31, 2017 March 31, 2016 Deferred tax asset attributable to: Net operating loss carryover $ 4,231,221 $ 3,129,170 Less: valuation allowance (4,231,221 ) (3,129,170 ) Net deferred tax asset $ — $ —

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)shares	Mar. 31, 2013shares	May 09, 2017$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation		Aug. 9, 2010
Cancellation of loans | $
Common Stock, Shares Authorized		2,000,000,000	2,000,000,000			375,030,000	2,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares		$ .001	$ .001				$ 0.001	$ 0.001	$ 0.001
Stock split ratio	0.05	0.05	0.01			4.1671
Cash and cash equivalent | $		$ 40,903
Intangible assets | $		$ 0
Impairment of intangible asset | $			$ 0	$ 82,120	$ 0
Reserved common shares		195,002
Stock options granted		29,000,000	195,000	9,875
Computer equipment		3 years
Options granted, number of shares		29,000,000	195,000	9,875	23,752
Options, exercise price | $ / shares		$ 0.001
Sale Agmt
Date of Agreement		Jul. 19, 2013
Cancellation of loans | $		$ 28,818
Shares sold by former officers		265,646
Shares returned to treasury		250,128
Shares agreed to cancel		131,261
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013
Common Stock, shares issued		41,384
Series A Preferred Stock, shares issued		6,000,000
Stock Value | $		$ 123,973
Termination of agreement | $		20,000
Additional cash required | $		$ 2,000,000

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Computer equipment	$ 5,160	$ 5,160
Less: accumulated depreciation	(3,035)	(1,429)
Property and equipment, net	$ 2,125	$ 3,731

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property And Equipment Details Narrative
Depreciation expense	$ 1,606	$ 799
Computer equipment	3 years

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Impairment of intangible asset		$ 0	$ 82,120	$ 0
Asset Assign Agmt
Date of Agreement	Jul. 18, 2013
Common Stock, shares issued	41,384
Series A Preferred Stock, shares issued	6,000,000
Stock Value	$ 123,973
Asset Assign Agmt #2
Date of Agreement	Oct. 6, 2014
Common Stock, shares issued	110,396
Common stock, value	$ 7,904,355
Impaired Assets	0
Impairment of intangible asset	$ 82,120

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Payables and Accruals [Abstract]
Wages and taxes	$ 829,231	$ 514,713
Accrued interest	108,552	15,437
Total accrued expenses	$ 937,783	$ 530,150

Related Party Debt and Transa30

Related Party Debt and Transactions (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	May 15, 2017
Cancellation of loans
Due to related parties	49,395	$ 76,913
Loans and interest received (repaid) from/to related parties	(27,518)	70,846
Interest expense, related party	(536)	(300)
Accrued expenses	937,783	530,150
SH Loan #1
Loan from related party			$ 6,000
Interest Rate			8.00%
SH Loan #2
Loan from related party	$ 6,280
Interest Rate	8.00%
Interest expense, related party	$ 903	267
Related Party Loans
Repayment of loans to related parties	36,300
Accrued expenses	14,450	22,200		$ 5,300
Accrued expenses, balance due	$ 350
Employment Agmt
Date of Agreement	Sep. 6, 2013
Term of Agreement	2 years
Annual Compensation	$ 275,000
Options to purchase	1,500
Options to purchase, exercise price	$ 40
Bonus	$ 68,750
Earnings	275,000	275,000
Accrued Earnings	$ 645,945	$ 395,630

Note Payable (Details Narrative

Note Payable (Details Narrative)	12 Months Ended
	Mar. 31, 2017USD ($)
Note Payable #1
Date of Agreement	Aug. 13, 2014
Convertible Note	$ 900,000
Interest Rate	10.00%
Due Date	Aug. 1, 2017
Interest Accrued	$ 74,959
Note Payable #2
Date of Agreement	Feb. 21, 2017
Convertible Note	$ 20,000
Interest Rate	8.00%
Due Date	Aug. 21, 2017
Interest Accrued	$ 167

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument, Converted Amount		$ 389,100	$ 602,374
Debt Instrument, Interest Accrued, Converted Amount		11,010
Convertible Prom Note #6
Date of Agreement				Aug. 13, 2014
Convertible Note				$ 61,111
Interest Rate				12.00%
Due Date				Aug. 14, 2016
Interest Accrued			0	$ 1,067
Convertible Note, Balance				0
Original Issue Discount				5,500
Debt Instrument, Converted Amount				61,111
Debt Instrument, Interest Accrued, Converted Amount			$ 1,067	$ 6,266
Common Stock, shares issued			8,892	70,185
Convertible Prom Note #8
Date of Agreement				Sep. 18, 2014
Convertible Note				$ 64,500
Interest Rate				12.00%
Due Date				Sep. 18, 2015
Interest Accrued			$ 0	$ 8,240
Convertible Note, Balance			0	54,500
Original Issue Discount				5,500
Debt Instrument, Converted Amount			54,500	$ 10,000
Debt Instrument, Interest Accrued, Converted Amount			$ 8,240
Common Stock, shares issued			93,980	9,091
Convertible Prom Note #9
Date of Agreement				Sep. 23, 2014
Convertible Note				$ 55,000
Interest Rate				8.00%
Due Date				Jun. 23, 2015
Interest Accrued			$ 0	$ 2,158
Convertible Note, Balance			0	29,800
Debt Instrument, Converted Amount			29,800	$ 25,200
Debt Instrument, Interest Accrued, Converted Amount			$ 2,158
Common Stock, shares issued			43,234	35,000
Convertible Prom Note #10
Date of Agreement			Oct. 6, 2014
Convertible Note			$ 33,000
Interest Rate			8.00%
Due Date			Jul. 6, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			33,000
Debt Instrument, Interest Accrued, Converted Amount			$ 1,320
Common Stock, shares issued			39,000
Convertible Prom Note #11
Date of Agreement			Nov. 6, 2014
Convertible Note			$ 55,000
Interest Rate			12.00%
Due Date			May 6, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			55,000
Debt Instrument, Interest Accrued, Converted Amount			$ 3,553
Common Stock, shares issued			140,682
Convertible Prom Note #12
Date of Agreement			Nov. 25, 2014
Convertible Note			$ 43,000
Interest Rate			8.00%
Due Date			Aug. 28, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			$ 46,510
Common Stock, shares issued			264,514
Fee			Default
Fee Amount			$ 3,510
Convertible Prom Note #13
Date of Agreement			Dec. 16, 2014
Convertible Note			$ 33,333
Interest Rate			12.00%
Due Date			Dec. 16, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Original Issue Discount			3,333
Debt Instrument, Converted Amount			33,333
Debt Instrument, Interest Accrued, Converted Amount			$ 4,000
Common Stock, shares issued			252,358
Convertible Prom Note #14
Date of Agreement			Jan. 9, 2015
Convertible Note			$ 33,000
Interest Rate			8.00%
Due Date			Oct. 13, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Interest Accrued, Converted Amount			$ 1,320
Common Stock, shares issued			423,500
Fee			Default
Fee Amount			$ 16,500
Convertible Prom Note #15
Date of Agreement			Feb. 5, 2015
Convertible Note			$ 54,000
Interest Rate			8.00%
Due Date			Nov. 9, 2015
Interest Accrued		0
Convertible Note, Balance		0	$ 47,980
Debt Instrument, Converted Amount			$ 33,020
Common Stock, shares issued			619,652
Fee			Default
Fee Amount			$ 27,000
Convertible Prom Note #16
Date of Agreement			Feb. 17, 2015
Convertible Note			$ 66,780
Interest Rate			8.00%
Due Date			Aug. 14, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0
Original Issue Discount			6,780
Debt Instrument, Converted Amount			66,780
Debt Instrument, Interest Accrued, Converted Amount			$ 3,148
Common Stock, shares issued			442,702
Convertible Prom Note #17
Date of Agreement			Feb. 25, 2015
Convertible Note			$ 27,778
Interest Rate			12.00%
Due Date			Feb. 25, 2017
Interest Accrued			$ 0
Convertible Note, Balance			0
Original Issue Discount			2,778
Debt Instrument, Converted Amount			27,778
Debt Instrument, Interest Accrued, Converted Amount			$ 3,333
Common Stock, shares issued			259,261
Convertible Prom Note #18
Date of Agreement			Mar. 9, 2015
Convertible Note			$ 55,000
Interest Rate			8.00%
Due Date			Jun. 23, 2017
Interest Accrued	$ 0	0	$ 0
Convertible Note, Balance	8,838	0	16,215
Debt Instrument, Converted Amount	7,377		38,785
Debt Instrument, Interest Accrued, Converted Amount	$ 422		$ 5,135
Common Stock, shares issued	2,324,229		2,886,693
Convertible Prom Note #19
Date of Agreement			Mar. 26, 2015
Convertible Note			$ 29,680
Interest Rate			8.00%
Due Date			Mar. 23, 2016
Interest Accrued		6,452	$ 2,577
Convertible Note, Balance			18,751
Original Issue Discount			1,680
Debt Instrument, Converted Amount			$ 10,929
Common Stock, shares issued			796,236
Convertible Prom Note #20
Date of Agreement				Mar. 2, 2015
Convertible Note				$ 58,300
Interest Rate				8.00%
Due Date				Aug. 14, 2015
Interest Accrued			$ 0
Convertible Note, Balance			0	$ 1,898
Original Issue Discount				3,300
Debt Instrument, Converted Amount			1,898	$ 56,402
Debt Instrument, Interest Accrued, Converted Amount			$ 20
Common Stock, shares issued			2,650	60,778
Convertible Prom Note #21
Date of Agreement			May 5, 2015
Convertible Note			$ 68,900
Interest Rate			8.00%
Due Date			May 5, 2016
Interest Accrued		0
Convertible Note, Balance		0
Original Issue Discount			$ 3,900
Debt Instrument, Converted Amount		60,439	8,461
Debt Instrument, Interest Accrued, Converted Amount		$ 6,839	$ 566
Common Stock, shares issued		44,551,004	906,763
Convertible Prom Note #22
Date of Agreement			May 6, 2015
Convertible Note			$ 10,500
Interest Rate			8.00%
Due Date			Feb. 8, 2016
Interest Accrued		$ 0
Convertible Note, Balance		0	$ 15,750
Fee			Default
Fee Amount		$ 5,250
Convertible Prom Note #23
Date of Agreement			May 27, 2015
Convertible Note			$ 16,500
Interest Rate			8.00%
Due Date			May 28, 2016
Interest Accrued			$ 0
Convertible Note, Balance			0
Debt Instrument, Converted Amount			16,500
Debt Instrument, Interest Accrued, Converted Amount			$ 344
Common Stock, shares issued			129,566
Convertible Prom Note #24
Date of Agreement		Aug. 28, 2015
Convertible Note		$ 15,000
Interest Rate		8.00%
Due Date		Aug. 28, 2016
Interest Accrued		$ 0
Convertible Note, Balance		0
Debt Instrument, Converted Amount		15,000
Debt Instrument, Interest Accrued, Converted Amount		$ 939
Common Stock, shares issued		4,351,619
Convertible Prom Note #25
Date of Agreement			Sep. 4, 2015
Convertible Note			$ 19,000
Interest Rate			8.00%
Due Date			Jun. 4, 2016
Interest Accrued		$ 0
Convertible Note, Balance		0
Convertible Prom Note #26
Date of Agreement			Dec. 29, 2015
Convertible Note			$ 57,378
Interest Rate			8.00%
Due Date			Jun. 23, 2017
Interest Accrued		0	$ 0
Convertible Note, Balance		$ 0	1,609
Debt Instrument, Converted Amount			59,934
Debt Instrument, Interest Accrued, Converted Amount			$ 1,222
Common Stock, shares issued			1,796,394
Fee			Default
Fee Amount			$ 4,165
Convertible Prom Note #27
Date of Agreement		Jan. 22, 2016
Convertible Note		$ 60,500
Interest Rate		10.00%
Due Date		Oct. 22, 2016
Interest Accrued		$ 7,194
Convertible Prom Note #28
Date of Agreement		Feb. 25, 2016
Convertible Note		$ 27,500
Interest Rate		8.00%
Due Date		Feb. 25, 2017
Interest Accrued		$ 0
Convertible Note, Balance		0
Original Issue Discount, unamortized		212
Debt Instrument, Converted Amount		16,745
Debt Instrument, Interest Accrued, Converted Amount		$ 1,380
Common Stock, shares issued		3,325,000
Convertible Prom Note #29
Date of Agreement		Mar. 24, 2016
Convertible Note		$ 7,500
Interest Rate		8.00%
Due Date		Mar. 24, 2017
Interest Accrued		$ 0
Convertible Prom Note #34
Date of Agreement		May 25, 2016
Convertible Note		$ 30,000
Interest Rate		8.00%
Due Date		May 25, 2017
Interest Accrued		$ 0
Convertible Note, Balance		$ 0
Convertible Prom Note #30
Date of Agreement		Jun. 8, 2016
Convertible Note		$ 84,250
Interest Rate		8.00%
Due Date		Jun. 8, 2017
Interest Accrued		$ 0
Convertible Note, Balance		$ 0
Convertible Prom Note #32
Date of Agreement		Jun. 23, 2016
Convertible Note		$ 56,000
Interest Rate		8.00%
Due Date		Jun. 23, 2017
Interest Accrued		$ 3,449
Convertible Prom Note #35
Date of Agreement		Jul. 7, 2016
Convertible Note		$ 58,000
Interest Rate		8.00%
Due Date		Jul. 7, 2017
Interest Accrued		$ 3,277
Convertible Prom Note #36
Date of Agreement		Oct. 20, 2016
Convertible Note		$ 32,000
Interest Rate		8.00%
Due Date		Oct. 20, 2017
Interest Accrued		$ 1,136
Convertible Prom Note #37
Date of Agreement		Nov. 17, 2016
Convertible Note		$ 56,000
Interest Rate		8.00%
Due Date		Jun. 23, 2017
Interest Accrued		$ 3,449
Convertible Prom Note #38
Date of Agreement		Jan. 5, 2017
Convertible Note		$ 285,000
Interest Rate		10.00%
Due Date		Oct. 5, 2017
Interest Accrued		$ 6,637
Convertible Note, Balance		20,001
Original Issue Discount		$ 30,000
Convertible Prom Note #39
Date of Agreement		Feb. 20, 2017
Convertible Note		$ 243,313
Interest Rate		8.00%
Due Date		Oct. 25, 2017
Interest Accrued		$ 890
Convertible Note, Balance		208,943
Debt Instrument, Converted Amount		34,370
Debt Instrument, Interest Accrued, Converted Amount		$ 1,124
Common Stock, shares issued		29,775,000
Convertible Prom Note #40
Date of Agreement		Feb. 21, 2017
Convertible Note		$ 15,000
Interest Rate		8.00%
Due Date		Oct. 25, 2017
Interest Accrued		$ 125
Convertible Prom Note #41
Date of Agreement		Feb. 22, 2017
Convertible Note		$ 59,799
Interest Rate		10.00%
Due Date		Oct. 25, 2017
Interest Accrued		$ 606
Convertible Prom Note #42
Date of Agreement		Feb. 22, 2017
Convertible Note		$ 20,900
Interest Rate		10.00%
Due Date		Oct. 22, 2017
Interest Accrued		$ 212

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Notes to Financial Statements
Change in value of derivative liability	$ 1,112,538	$ (563,432)
Derivative expense	(608,949)	(497,213)
Debt Discounts, Conversion Features	563,858
Debt Discount, Unamortized	356,819
Derivative liabilities	2,607,959	446,912
Derivative liabilities

Equity Transactions - Schedule

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Fair value allocation of proceeds	$ 45,466
Warrant #8
Date	Jun. 9, 2015
Warrants	$ 45,000
Stock price on grant date	$ .40
Exercise price	$ 0.40
Expected life	5 years
Volatility	98.00%
Risk-free rate	1.74%
Calculated value	$ 13,259
Fair value allocation of proceeds	$ 13,259
Warrant #9
Date	Dec. 15, 2015
Warrants	$ 200,000
Stock price on grant date	$ .20
Exercise price	$ .20
Expected life	5 years
Volatility	98.00%
Risk-free rate	1.71%
Calculated value	$ 29,612
Fair value allocation of proceeds	$ 29,612
Warrant #10
Date	Mar. 30, 2017
Warrants	$ 9,200,000
Stock price on grant date	$ 0.002
Exercise price	$ 0.002
Expected life	5 years
Volatility	120.00%
Risk-free rate	1.96%
Calculated value	$ 15,278
Fair value allocation of proceeds	$ 45,466

Equity Transactions - Schedul35

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	246,533
Beginning Balance, Average Exercise Price	$ 3.84
Issued, Warrants	9,200,000
Issued, Average Exercise Price	$ 0.002
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants	9,446,556	246,533
Ending Balance, Average Exercise Price	$ 0.102	$ 3.84

Equity Transactions - Schedul36

Equity Transactions - Schedule of Value of Options (Details)	12 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Stock Option 7
Date of Issuance	Apr. 6, 2015
Options | shares	102,000
Stock price on grant date	$ 1.60
Exercise price	1.60
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.31%
Calculated value | $	$ 120,778
Modified value | $	$ 151,221
Stock Option 8
Date of Issuance	Jun. 9, 2015
Options | shares	50,000
Stock price on grant date	$ 0.40
Exercise price	0.40
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	99.00%
Risk-free rate	1.74%
Calculated value | $	$ 14,838
Modified value | $	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015
Options | shares	43,000
Stock price on grant date	$ 0.20
Exercise price	0.20
Exercise price, modified	$ 0.20
Expected life	5 years
Volatility	84.00%
Risk-free rate	1.70%
Calculated value | $	$ 5,736
Modified value | $	$ 5,736
Stock Option 10
Date of Issuance	Mar. 30, 2017
Options | shares	29,000,000
Stock price on grant date	$ 0.002
Exercise price	$ 0.002
Expected life	5 years
Volatility	120.00%
Risk-free rate	1.93%
Calculated value | $	$ 48,017
Modified value | $	$ 48,017

Equity Transactions - Schedul37

Equity Transactions - Schedule of Option Activity (Details) - shares	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares	228,627
Beginning Balance, weighted average exercise price	0.20
Options granted, number of shares	29,000,000	195,000	9,875	23,752
Options granted, weighted average exercise price	0.002
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	29,228,627	228,627
Ending Balance, weighted average exercise price	0.004	0.20

Equity Transactions (Details Na

Equity Transactions (Details Narrative)	3 Months Ended		12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015shares	Mar. 31, 2014shares	Mar. 31, 2013shares	May 09, 2017$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares	Jul. 18, 2013shares
Common Stock, Shares Authorized		2,000,000,000	2,000,000,000	2,000,000,000			375,030,000	2,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares		$ .001	$ .001	$ .001				$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized		10,000,000	10,000,000	10,000,000
Preferred Stock, Par Value | $ / shares		$ .001	$ .001	$ .001
Series A Preferred Stock, Designated											6,000,000
Common Stock, Issued		101,446,215	101,446,215	10,818,213
Preferred Stock, Issued		6,000,000	6,000,000	6,000,000
Stock split ratio	0.05		0.05	0.01			4.1671
Options granted, number of shares			29,000,000	195,000	9,875	23,752
Shares issued for services, value | $			$ 48,016	$ 48,016
Debt Instrument, Converted Amount | $			389,100	602,374
Stock-based compensation | $			$ 48,016	$ 240,999
Debt Conversion #26
Date of Issuance			Apr. 1, 2015
Common Stock, shares issued			20,556
Common Stock, price per share | $ / shares			$ 0.81000
Debt Instrument, Converted Amount | $			$ 16,650
Debt Conversion #27
Date of Issuance			Apr. 6, 2015
Common Stock, shares issued			10,482
Common Stock, price per share | $ / shares			$ .95400
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #28
Date of Issuance			Apr. 8, 2015
Common Stock, shares issued			22,678
Common Stock, price per share | $ / shares			$ .67500
Debt Instrument, Converted Amount | $			$ 15,309
Debt Conversion #29
Date of Issuance			Apr. 9, 2015
Common Stock, shares issued			16,273
Common Stock, price per share | $ / shares			$ .88000
Debt Instrument, Converted Amount | $			$ 14,320
Debt Conversion #30
Date of Issuance			Apr. 14, 2015
Common Stock, shares issued			11,848
Common Stock, price per share | $ / shares			$ .88000
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #31
Date of Issuance			Apr. 16, 2015
Common Stock, shares issued			2,650
Common Stock, price per share | $ / shares			$ .72380
Debt Instrument, Converted Amount | $			$ 1,918
Debt Conversion #32
Date of Issuance			Apr. 21, 2015
Common Stock, shares issued			12,987
Common Stock, price per share | $ / shares			$ .77000
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #33
Date of Issuance			Apr. 29, 2015
Common Stock, shares issued			19,481
Common Stock, price per share | $ / shares			$ .77000
Debt Instrument, Converted Amount | $			$ 15,000
Debt Conversion #34
Date of Issuance			May 4, 2015
Common Stock, shares issued			6,573
Common Stock, price per share | $ / shares			$ .77320
Debt Instrument, Converted Amount | $			$ 5,083
Debt Conversion #35
Date of Issuance			May 12, 2015
Common Stock, shares issued			45,169
Common Stock, price per share | $ / shares			$ .63000
Debt Instrument, Converted Amount | $			$ 28,456
Debt Conversion #36
Date of Issuance			May 20, 2015
Common Stock, shares issued			47,382
Common Stock, price per share | $ / shares			$ .42620
Debt Instrument, Converted Amount | $			$ 20,199
Debt Conversion #37
Date of Issuance			May 20, 2015
Common Stock, shares issued			39,182
Common Stock, price per share | $ / shares			$ .44000
Debt Instrument, Converted Amount | $			$ 17,240
Debt Conversion #38
Date of Issuance			May 27, 2015
Common Stock, shares issued			35,090
Common Stock, price per share | $ / shares			$ .38660
Debt Instrument, Converted Amount | $			$ 13,568
Debt Conversion #39
Date of Issuance			May 29, 2015
Common Stock, shares issued			44,118
Common Stock, price per share | $ / shares			$ .34000
Debt Instrument, Converted Amount | $			$ 15,000
Debt Conversion #40
Date of Issuance			Jun. 11, 2015
Common Stock, shares issued			47,130
Common Stock, price per share | $ / shares			$ .21000
Debt Instrument, Converted Amount | $			$ 9,897
Debt Conversion #41
Date of Issuance			Jun. 16, 2015
Common Stock, shares issued			58,750
Common Stock, price per share | $ / shares			$ .24000
Debt Instrument, Converted Amount | $			$ 14,100
Debt Conversion #42
Date of Issuance			Jun. 16, 2015
Common Stock, shares issued			56,521
Common Stock, price per share | $ / shares			$ .24000
Debt Instrument, Converted Amount | $			$ 13,565
Debt Conversion #44
Date of Issuance			Jun. 22, 2015
Common Stock, shares issued			61,792
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 7,415
Debt Conversion #45
Date of Issuance			Jun. 22, 2015
Common Stock, shares issued			123,996
Common Stock, price per share | $ / shares			$ .11600
Debt Instrument, Converted Amount | $			$ 14,384
Debt Conversion #46
Date of Issuance			Jun. 23, 2015
Common Stock, shares issued			64,600
Common Stock, price per share | $ / shares			$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,752
Debt Conversion #47
Date of Issuance			Sep. 16, 2015
Common Stock, shares issued			88,602
Common Stock, price per share | $ / shares			$ .0900
Debt Instrument, Converted Amount | $			$ 7,974
Debt Conversion #48
Date of Issuance			Sep. 28, 2015
Common Stock, shares issued			83,333
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #49
Date of Issuance			Sep. 29, 2015
Common Stock, shares issued			88,500
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 10,620
Debt Conversion #50
Date of Issuance			Oct. 7, 2015
Common Stock, shares issued			18,750
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 2,250
Debt Conversion #51
Date of Issuance			Oct. 7, 2015
Common Stock, shares issued			70,000
Common Stock, price per share | $ / shares			$ 0.12000
Debt Instrument, Converted Amount | $			$ 8,400
Debt Conversion #52
Date of Issuance			Oct. 19, 2015
Common Stock, shares issued			81,000
Common Stock, price per share | $ / shares			$ 0.12000
Debt Instrument, Converted Amount | $			$ 9,720
Debt Conversion #53
Date of Issuance			Nov. 2, 2015
Common Stock, shares issued			98,306
Common Stock, price per share | $ / shares			$ .04500
Debt Instrument, Converted Amount | $			$ 4,424
Debt Conversion #54
Date of Issuance			Nov. 23, 2015
Common Stock, shares issued			83,333
Common Stock, price per share | $ / shares			$ 0.12000
Debt Instrument, Converted Amount | $			$ 10,000
Debt Conversion #55
Date of Issuance			Nov. 30, 2015
Common Stock, shares issued			129,566
Common Stock, price per share | $ / shares			$ .13000
Debt Instrument, Converted Amount | $			$ 16,844
Debt Conversion #56
Date of Issuance			Dec. 9, 2015
Common Stock, shares issued			38,800
Common Stock, price per share | $ / shares			$ .04500
Debt Instrument, Converted Amount | $			$ 1,746
Debt Conversion #57
Date of Issuance			Dec. 17, 2015
Common Stock, shares issued			45,966
Common Stock, price per share | $ / shares			$ 0.12000
Debt Instrument, Converted Amount | $			$ 5,332
Debt Conversion #58
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			38,800
Common Stock, price per share | $ / shares			$ .04500
Debt Instrument, Converted Amount | $			$ 1,341
Debt Conversion #59
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			147,500
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 17,700
Debt Conversion #60
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			119,208
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 14,305
Debt Conversion #61
Date of Issuance			Dec. 28, 2015
Common Stock, shares issued			128,996
Common Stock, price per share | $ / shares			$ .11600
Debt Instrument, Converted Amount | $			$ 14,963
Debt Conversion #62
Date of Issuance			Dec. 29, 2015
Common Stock, shares issued			69,958
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 8,395
Debt Conversion #63
Date of Issuance			Dec. 29, 2015
Common Stock, shares issued			63,917
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 7,670
Debt Conversion #64
Date of Issuance			Dec. 30, 2015
Common Stock, shares issued			147,812
Common Stock, price per share | $ / shares			$ .04500
Debt Instrument, Converted Amount | $			$ 6,651
2013 Stock Option Plan Amendment
Stock-based compensation | $			$ 50,448
2013 Stock Option Plan Amdt #2
Date of Agreement			Apr. 6, 2015
Options granted, number of shares			135,627
Exercise price | $ / shares			$ 1.60
Stock-based compensation | $			$ 9,316
2013 Stock Option Plan Amdt #3
Date of Agreement			Aug. 4, 2015
Options granted, number of shares			185,627
Exercise price | $ / shares			$ 1.60
Stock-based compensation | $			$ 47,463
Debt Conversion #65
Date of Issuance			Jan. 4, 2016
Common Stock, shares issued			161,161
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 19,339
Debt Conversion #66
Date of Issuance			Jan. 5, 2016
Common Stock, shares issued			180,161
Common Stock, price per share | $ / shares			$ .04500
Debt Instrument, Converted Amount | $			$ 8,107
Debt Conversion #67
Date of Issuance			Jan. 6, 2016
Common Stock, shares issued			133,917
Common Stock, price per share | $ / shares			$ .12000
Debt Instrument, Converted Amount | $			$ 16,070
Debt Conversion #68
Date of Issuance			Jan. 6, 2016
Common Stock, shares issued			143,080
Common Stock, price per share | $ / shares			$ .1160
Debt Instrument, Converted Amount | $			$ 16,597
Debt Conversion #69
Date of Issuance			Feb. 16, 2016
Common Stock, shares issued			211,020
Common Stock, price per share | $ / shares			$ .0068
Debt Instrument, Converted Amount | $			$ 1,424
Debt Conversion #70
Date of Issuance			Feb. 17, 2016
Common Stock, shares issued			422,164
Common Stock, price per share | $ / shares			$ .03040
Debt Instrument, Converted Amount | $			$ 12,800
Debt Conversion #71
Date of Issuance			Feb. 23, 2016
Common Stock, shares issued			210,909
Common Stock, price per share | $ / shares			$ .02200
Debt Instrument, Converted Amount | $			$ 4,640
Debt Conversion #72
Date of Issuance			Feb. 23, 2016
Common Stock, shares issued			210,044
Common Stock, price per share | $ / shares			$ .01460
Debt Instrument, Converted Amount | $			$ 3,086
Debt Conversion #73
Date of Issuance			Feb. 24, 2016
Common Stock, shares issued			220,999
Common Stock, price per share | $ / shares			$ .00680
Debt Instrument, Converted Amount | $			$ 1,492
Debt Conversion #74
Date of Issuance			Feb. 25, 2016
Common Stock, shares issued			131,949
Common Stock, price per share | $ / shares			$ .02280
Debt Instrument, Converted Amount | $			$ 3,000
Debt Conversion #75
Date of Issuance			Feb. 25, 2016
Common Stock, shares issued			210,909
Common Stock, price per share | $ / shares			$ .02200
Debt Instrument, Converted Amount | $			$ 4,640
Debt Conversion #76
Date of Issuance			Mar. 1, 2016
Common Stock, shares issued			291,723
Common Stock, price per share | $ / shares			$ .0040
Debt Instrument, Converted Amount | $			$ 1,313
Debt Conversion #77
Date of Issuance			Mar. 2, 2016
Common Stock, shares issued			291,582
Common Stock, price per share | $ / shares			$ .01580
Debt Instrument, Converted Amount | $			$ 4,600
Debt Conversion #78
Date of Issuance			Mar. 2, 2016
Common Stock, shares issued			129,321
Common Stock, price per share | $ / shares			$ .01280
Debt Instrument, Converted Amount | $			$ 1,650
Debt Conversion #79
Date of Issuance			Mar. 2, 2016
Common Stock, shares issued			582,500
Common Stock, price per share | $ / shares			$ .01600
Debt Instrument, Converted Amount | $			$ 9,332
Debt Conversion #80
Date of Issuance			Mar. 7, 2016
Common Stock, shares issued			327,315
Common Stock, price per share | $ / shares			$ .00860
Debt Instrument, Converted Amount | $			$ 2,799
Debt Conversion #81
Date of Issuance			Mar. 11, 2016
Common Stock, shares issued			207,375
Common Stock, price per share | $ / shares			$ .00920
Debt Instrument, Converted Amount | $			$ 1,924
Debt Conversion #82
Date of Issuance			Mar. 14, 2016
Common Stock, shares issued			356,289
Common Stock, price per share | $ / shares			$ .00640
Debt Instrument, Converted Amount | $			$ 2,245
Debt Conversion #83
Date of Issuance			Mar. 15, 2016
Common Stock, shares issued			372,705
Common Stock, price per share | $ / shares			$ .00900
Debt Instrument, Converted Amount | $			$ 3,329
Debt Conversion #84
Date of Issuance			Mar. 15, 2016
Common Stock, shares issued			572,500
Common Stock, price per share | $ / shares			$ .00920
Debt Instrument, Converted Amount | $			$ 5,210
Debt Conversion #85
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			447,894
Common Stock, price per share | $ / shares			$ .00540
Debt Instrument, Converted Amount | $			$ 2,419
Debt Conversion #86
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			360,024
Common Stock, price per share | $ / shares			$ .00660
Debt Instrument, Converted Amount | $			$ 2,367
Debt Conversion #87
Date of Issuance			Mar. 22, 2016
Common Stock, shares issued			584,100
Common Stock, price per share | $ / shares			$ .00920
Debt Instrument, Converted Amount | $			$ 5,315
Debt Conversion #88
Date of Issuance			Mar. 28, 2016
Common Stock, shares issued			447,930
Common Stock, price per share | $ / shares			$ .00440
Debt Instrument, Converted Amount | $			$ 1,986
Debt Conversion #89
Date of Issuance			Apr. 1, 2016
Common Stock, shares issued			488,316
Common Stock, price per share | $ / shares			$ .00450
Debt Instrument, Converted Amount | $			$ 2,197
Debt Conversion #90
Date of Issuance			Apr. 4, 2016
Common Stock, shares issued			862,500
Common Stock, price per share | $ / shares			$ .00562
Debt Instrument, Converted Amount | $			$ 4,847
Debt Conversion #91
Date of Issuance			Apr. 7, 2016
Common Stock, shares issued			486,111
Common Stock, price per share | $ / shares			$ .00360
Debt Instrument, Converted Amount | $			$ 1,750
Debt Conversion #92
Date of Issuance			Apr. 14, 2016
Common Stock, shares issued			962,500
Common Stock, price per share | $ / shares			$ .00432
Debt Instrument, Converted Amount | $			$ 4,158
Debt Conversion #93
Date of Issuance			Apr. 15, 2016
Common Stock, shares issued			488,311
Common Stock, price per share | $ / shares			$ .00270
Debt Instrument, Converted Amount | $			$ 1,318
Debt Conversion #94
Date of Issuance			Apr. 26, 2016
Common Stock, shares issued			631,489
Common Stock, price per share | $ / shares			$ .00270
Debt Instrument, Converted Amount | $			$ 1,705
Debt Conversion #95
Date of Issuance			May 4, 2016
Common Stock, shares issued			485,901
Common Stock, price per share | $ / shares			$ .00426
Debt Instrument, Converted Amount | $			$ 2,067
Debt Conversion #96
Date of Issuance			May 31, 2016
Common Stock, shares issued			230,003
Common Stock, price per share | $ / shares			$ .00360
Debt Instrument, Converted Amount | $			$ 828
Debt Conversion #97
Date of Issuance			Jun. 2, 2016
Common Stock, shares issued			1,500,000
Common Stock, price per share | $ / shares			$ .00608
Debt Instrument, Converted Amount | $			$ 9,120
Debt Conversion #98
Date of Issuance			Jun. 2, 2016
Common Stock, shares issued			1,467,017
Common Stock, price per share | $ / shares			$ .00300
Debt Instrument, Converted Amount | $			$ 4,401
Debt Conversion #99
Date of Issuance			Jun. 14, 2016
Common Stock, shares issued			1,461,795
Common Stock, price per share | $ / shares			$ .00400
Debt Instrument, Converted Amount | $			$ 5,847
Debt Conversion #100
Date of Issuance			Jun. 17, 2016
Common Stock, shares issued			1,422,808
Common Stock, price per share | $ / shares			$ .00400
Debt Instrument, Converted Amount | $			$ 5,691
Debt Conversion #101
Date of Issuance			Jun. 29, 2017
Common Stock, shares issued			1,063,518
Common Stock, price per share | $ / shares			$ .00618
Debt Instrument, Converted Amount | $			$ 6,580
Debt Conversion #102
Date of Issuance			Aug. 23, 2016
Common Stock, shares issued			1,106,487
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,567
Debt Conversion #103
Date of Issuance			Aug. 29, 2016
Common Stock, shares issued			1,107,806
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,570
Debt Conversion #104
Date of Issuance			Sep. 6, 2016
Common Stock, shares issued			1,097,634
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,547
Debt Conversion #105
Date of Issuance			Sep. 20, 2016
Common Stock, shares issued			1,263,383
Common Stock, price per share | $ / shares			$ .00194
Debt Instrument, Converted Amount | $			$ 2,443
Debt Conversion #106
Date of Issuance			Sep. 26, 2016
Common Stock, shares issued			1,269,672
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,946
Debt Conversion #107
Date of Issuance			Sep. 28, 2016
Common Stock, shares issued			1,270,172
Common Stock, price per share | $ / shares			$ .00232
Debt Instrument, Converted Amount | $			$ 2,947
Debt Conversion #108
Date of Issuance			Sep. 30, 2016
Common Stock, shares issued			2,553,336
Common Stock, price per share | $ / shares			$ .00154
Debt Instrument, Converted Amount | $			$ 3,949
Debt Conversion #109
Date of Issuance			Oct. 7, 2016
Common Stock, shares issued			2,914,578
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,381
Debt Conversion #110
Date of Issuance			Oct. 14, 2016
Common Stock, shares issued			2,913,784
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,380
Debt Conversion #111
Date of Issuance			Oct. 21, 2016
Common Stock, shares issued			2,917,784
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,385
Debt Conversion #112
Date of Issuance			Oct. 26, 2016
Common Stock, shares issued			2,915,828
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 3,382
Debt Conversion #113
Date of Issuance			Oct. 31, 2016
Common Stock, shares issued			4,341,853
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,037
Debt Conversion #114
Date of Issuance			Nov. 7, 2016
Common Stock, shares issued			4,323,647
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,015
Debt Conversion #115
Date of Issuance			Nov. 22, 2016
Common Stock, shares issued			4,753,009
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,513
Debt Conversion #116
Date of Issuance			Nov. 29, 2016
Common Stock, shares issued			4,754,647
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 5,515
Debt Conversion #117
Date of Issuance			Dec. 6, 2016
Common Stock, shares issued			3,497,966
Common Stock, price per share | $ / shares			$ .00116
Debt Instrument, Converted Amount | $			$ 4,058
Debt Conversion #118
Date of Issuance		Jan. 10, 2017
Common Stock, shares issued		6,301,150
Common Stock, price per share | $ / shares		$ 0.00100
Debt Instrument, Converted Amount | $		$ 6,301
Debt Conversion #119
Date of Issuance		Feb. 22, 2017
Common Stock, shares issued		3,575,000
Common Stock, price per share | $ / shares		$ 0.00120
Debt Instrument, Converted Amount | $		$ 4,290
Debt Conversion #120
Date of Issuance		Mar. 13, 2017
Common Stock, shares issued		3,400,000
Common Stock, price per share | $ / shares		$ 0.00120
Debt Instrument, Converted Amount | $		$ 4,080
Debt Conversion #121
Date of Issuance		Mar. 21, 2017
Common Stock, shares issued		4,100,000
Common Stock, price per share | $ / shares		$ 0.00120
Debt Instrument, Converted Amount | $		$ 4,920
Debt Conversion #122
Date of Issuance		Mar. 22, 2017
Common Stock, shares issued		4,300,000
Common Stock, price per share | $ / shares		$ 0.00120
Debt Instrument, Converted Amount | $		$ 5,160
Debt Conversion #123
Date of Issuance		Mar. 24, 2017
Common Stock, shares issued		4,550,000
Common Stock, price per share | $ / shares		$ 0.00120
Debt Instrument, Converted Amount | $		$ 5,460
Debt Conversion #124
Date of Issuance		Mar. 30, 2017
Common Stock, shares issued		4,800,000
Common Stock, price per share | $ / shares		$ 0.00118
Debt Instrument, Converted Amount | $		$ 5,645
Debt Conversion #125
Date of Issuance		Mar. 31, 2017
Common Stock, shares issued		5,050,000
Common Stock, price per share | $ / shares		$ 0.00118
Debt Instrument, Converted Amount | $		$ 5,939
Asset Assign Agmt
Date of Agreement			Jul. 18, 2015
Common Stock, shares issued			41,384
Series A Preferred Stock, shares issued			6,000,000
Shares Issued, Value | $			$ 123,973
Sale Agmt
Shares agreed to cancel			131,261
Shares returned to treasury			250,128
Date of Agreement			Jul. 19, 2013
Warrant #1
Exercise Date			Oct. 29, 2013
Warrants | $			$ 125
Stock price on grant date | $ / shares			$ 600
Exercise price | $ / shares			$ 1,000
Expected life			1 year
Warrant #2
Exercise Date			Dec. 11, 2013
Warrants | $			$ 125
Stock price on grant date | $ / shares			$ 600
Exercise price | $ / shares			$ 1,000
Expected life			1 year
Warrant #3
Exercise Date			Jun. 9, 2015
Warrants | $			$ 45,000
Exercise price | $ / shares			$ 0.40
Expected life			5 years
Warrant #4
Exercise Date			Dec. 15, 2016
Warrants | $			$ 200,000
Exercise price | $ / shares			$ 0.20
Expected life			5 years
Sale of Stock #1
Issuance of common stock for cash, shares			5,019
Issuance of common stock for cash, amount | $			$ 5,405
Date of Issuance			Apr. 22, 2015
Sale of Stock #2
Issuance of common stock for cash, shares			77,123
Issuance of common stock for cash, amount | $			$ 10,797
Date of Issuance			Jun. 25, 2015
Sale of Stock #3
Issuance of common stock for cash, shares			80,971
Issuance of common stock for cash, amount | $			$ 11,336
Date of Issuance			Jul. 7, 2015
Sale of Stock #4
Issuance of common stock for cash, shares			71,964
Issuance of common stock for cash, amount | $			$ 10,075
Date of Issuance			Jul. 15, 2015
Sale of Stock #5
Issuance of common stock for cash, shares			82,442
Issuance of common stock for cash, amount | $			$ 11,542
Date of Issuance			Oct. 27, 2015

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	12 Months Ended
	Mar. 31, 2017USD ($)
Monthly Rent	$ 2,800
Contract
Date of Agreement	Jul. 8, 2016
Contract Duration	27 months
Contract Committment Value	$ 193,255

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax (Details) - USD ($)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Federal income tax benefit attributable to:
Current operations	$ 1,102,052	$ 601,276
Less: valuation allowance	(1,102,052)	(601,276)
Net provision for Federal income taxes

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Asset (Details) - USD ($)	Mar. 31, 2017	Mar. 31, 2016
Deferred tax asset attributable to:
Net operating loss carryover	$ 4,231,221	$ 3,129,170
Less: valuation allowance	(4,231,221)	(3,129,170)
Net deferred tax asset

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Mar. 31, 2017USD ($)
Income Tax Disclosure [Abstract]
Net Operating Loss Carry-Forwards	$ 12,444,769
Operating Loss Carry-Forwards Expiration Date	Jan. 1, 2034
Effective Tax Rate	34.00%

Subsequent Event (Details Narra

Subsequent Event (Details Narrative)	3 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)shares	Mar. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2013shares	May 15, 2017USD ($)	May 09, 2017$ / sharesshares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Debt Instrument, Converted Amount		$ 389,100	$ 602,374
Debt Instrument, Interest Accrued, Converted Amount		$ 11,010
Common Stock, Par Value | $ / shares		$ .001	$ .001			$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized | shares		2,000,000,000	2,000,000,000	375,030,000		2,000,000,000	375,030,000	900,000
Stock split ratio	0.05	0.05	0.01	4.1671
Accrued expenses		$ 937,783	$ 530,150
Related Party Loans
Interest Rate	0.00%
Due Date	May 15, 2018
Accrued expenses		$ 14,450	$ 22,200		$ 5,300
Consulting Agmt
Date of Agreement	Jul. 7, 2017
Term of Agreement	2 years
Annual Compensation	$ 180,000
Collaboration Agmt
Date of Agreement	Jul. 11, 2017
Account Receivable	$ 100,000
Common Stock, Receivable | shares	15,000,000
Convertible Prom Note #43
Date of Agreement	Apr. 4, 2017
Convertible Note	$ 71,457
Interest Rate	8.00%
Due Date	Jan. 8, 2018
Convertible Prom Note #44
Date of Agreement	Apr. 18, 2017
Convertible Note	$ 115,000
Interest Rate	10.00%
Due Date	Jan. 30, 2018
Original Issue Discount	$ 11,500
Debt Conversion #126
Date of Issuance	Apr. 5, 2017
Debt Instrument, Converted Amount	$ 6,004
Debt Instrument, Interest Accrued, Converted Amount	$ 229
Common Stock, shares issued | shares	5,300,000
Debt Conversion #127
Date of Issuance	Apr. 10, 2017
Debt Instrument, Converted Amount	$ 6,363
Debt Instrument, Interest Accrued, Converted Amount	$ 222
Common Stock, shares issued | shares	5,600,000
Debt Conversion #128
Date of Issuance	Apr. 11, 2017
Debt Instrument, Converted Amount	$ 6,004
Debt Instrument, Interest Accrued, Converted Amount	$ 43
Common Stock, shares issued | shares	5,850,000
Debt Conversion #129
Date of Issuance	Apr. 18, 2017
Debt Instrument, Converted Amount	$ 7,000
Debt Instrument, Interest Accrued, Converted Amount	$ 291
Common Stock, shares issued | shares	6,200,000
Debt Conversion #130
Date of Issuance	Apr. 20, 2017
Debt Instrument, Converted Amount	$ 7,564
Debt Instrument, Interest Accrued, Converted Amount	$ 80
Common Stock, shares issued | shares	6,500,000
Debt Conversion #131
Date of Issuance	Apr. 21, 2017
Debt Instrument, Converted Amount	$ 16,426
Debt Instrument, Interest Accrued, Converted Amount	$ 38
Common Stock, shares issued | shares	14,000,000
Debt Conversion #132
Date of Issuance	Apr. 25, 2017
Debt Instrument, Converted Amount	$ 17,148
Debt Instrument, Interest Accrued, Converted Amount	$ 139
Common Stock, shares issued | shares	14,700,000
Debt Conversion #133
Date of Issuance	Apr. 26, 2017
Debt Instrument, Converted Amount	$ 25,000
Debt Instrument, Interest Accrued, Converted Amount	$ 1,600
Common Stock, shares issued | shares	26,600,000
Debt Conversion #134
Date of Issuance	May 1, 2017
Debt Instrument, Converted Amount	$ 8,514
Debt Instrument, Interest Accrued, Converted Amount	$ 186
Common Stock, shares issued | shares	14,500,000
Debt Conversion #135
Date of Issuance	Jun. 13, 2017
Debt Instrument, Interest Accrued, Converted Amount	$ 1,200
Common Stock, shares issued | shares	10,000,000
Debt Conversion #136
Date of Issuance	Jun. 16, 2017
Debt Instrument, Converted Amount	$ 1,158
Debt Instrument, Interest Accrued, Converted Amount	$ 142
Common Stock, shares issued | shares	11,000,000
Debt Conversion #137
Date of Issuance	Jun. 16, 2017
Debt Instrument, Converted Amount	$ 1,795
Debt Instrument, Interest Accrued, Converted Amount	$ 135
Common Stock, shares issued | shares	19,299,400
Debt Conversion #138
Date of Issuance	Jun. 20, 2017
Debt Instrument, Converted Amount	$ 1,276
Debt Instrument, Interest Accrued, Converted Amount	$ 116
Common Stock, shares issued | shares	11,600,000
Debt Conversion #139
Date of Issuance	Jun. 21, 2017
Debt Instrument, Converted Amount	$ 2,150
Debt Instrument, Interest Accrued, Converted Amount	$ 164
Common Stock, shares issued | shares	23,139,900
Debt Conversion #140
Date of Issuance	Jun. 22, 2017
Debt Instrument, Converted Amount	$ 1,413
Debt Instrument, Interest Accrued, Converted Amount	$ 57
Common Stock, shares issued | shares	12,250,000
Debt Conversion #141
Date of Issuance	Jun. 22, 2017
Debt Instrument, Converted Amount	$ 1,590
Common Stock, shares issued | shares	13,250,000
Debt Conversion #142
Date of Issuance	Jun. 26, 2017
Debt Instrument, Converted Amount	$ 1,688
Debt Instrument, Interest Accrued, Converted Amount	$ 112
Common Stock, shares issued | shares	15,000,000
Debt Conversion #143
Date of Issuance	Jun. 29, 2017
Debt Instrument, Converted Amount	$ 1,897
Debt Instrument, Interest Accrued, Converted Amount	$ 83
Common Stock, shares issued | shares	16,500,000
Debt Conversion #144
Date of Issuance	Jul. 3, 2017
Debt Instrument, Converted Amount	$ 1,979
Debt Instrument, Interest Accrued, Converted Amount	$ 109
Common Stock, shares issued | shares	17,400,000
Debt Conversion #145
Date of Issuance	Jul. 12, 2017
Debt Instrument, Interest Accrued, Converted Amount	$ 2,088
Common Stock, shares issued | shares	17,400,000
Debt Conversion #146
Date of Issuance	Jul. 13, 2017
Debt Instrument, Converted Amount	$ 1,344
Debt Instrument, Interest Accrued, Converted Amount	$ 1,140
Common Stock, shares issued | shares	13,800,000
Debt Conversion #147
Date of Issuance	Jul. 14, 2017
Debt Instrument, Converted Amount	$ 3,358
Debt Instrument, Interest Accrued, Converted Amount	$ 16
Common Stock, shares issued | shares	19,000,000
Debt Conversion #148
Date of Issuance	Jul. 3, 2017
Debt Instrument, Converted Amount	$ 3,314
Debt Instrument, Interest Accrued, Converted Amount	$ 60
Common Stock, shares issued | shares	19,000,000
Debt Conversion #149
Date of Issuance	Jul. 20, 2017
Debt Instrument, Converted Amount	$ 3,554
Debt Instrument, Interest Accrued, Converted Amount	$ 28
Common Stock, shares issued | shares	19,900,000
Debt Conversion #150
Date of Issuance	Jul. 24, 2017
Debt Instrument, Converted Amount	$ 6,217
Debt Instrument, Interest Accrued, Converted Amount	$ 53
Common Stock, shares issued | shares	20,900,000
Debt Conversion #151
Date of Issuance	Jul. 25, 2017
Debt Instrument, Converted Amount	$ 6,022
Debt Instrument, Interest Accrued, Converted Amount	$ 848
Common Stock, shares issued | shares	22,900,000
Debt Conversion #152
Date of Issuance	Jul. 28, 2017
Debt Instrument, Converted Amount	$ 7,089
Debt Instrument, Interest Accrued, Converted Amount	$ 111
Common Stock, shares issued | shares	24,000,000
Debt Conversion #153
Date of Issuance	Aug. 2, 2017
Debt Instrument, Converted Amount	$ 7,035
Debt Instrument, Interest Accrued, Converted Amount	$ 165
Common Stock, shares issued | shares	24,000,000
Debt Conversion #154
Date of Issuance	Aug. 4, 2017
Debt Instrument, Converted Amount	$ 8,942
Debt Instrument, Interest Accrued, Converted Amount	$ 58
Common Stock, shares issued | shares	25,000,000
Debt Conversion #155
Date of Issuance	Aug. 8, 2017
Debt Instrument, Converted Amount	$ 11,022
Debt Instrument, Interest Accrued, Converted Amount	$ 97
Common Stock, shares issued | shares	26,475,000
Debt Conversion #156
Date of Issuance	Aug. 11, 2017
Debt Instrument, Converted Amount	$ 13,920
Common Stock, shares issued | shares	29,000,000
Debt Conversion #157
Date of Issuance	Aug. 16, 2017
Debt Instrument, Converted Amount	$ 12,810
Common Stock, shares issued | shares	30,500,000